Table 3.

12-month cumulative incidence, adjusted for the competing risk of death, of overall CAT and CAT location among California cancer patients with 13 common cancers, 2005-2017

Overall CATPE±DVTpDVTiDDVTLE-NOS, DVT
Cancer site% (95% CI)% (95% CI)% (95% CI)% (95% CI)% (95% CI)
Breast  
 Overall 1.04 (1.00, 1.09) 0.65 (0.62, 0.69) 0.17 (0.15, 0.19) 0.10 (0.09, 0.12) 0.12 (0.11, 0.14) 
 Stage I 0.53 (0.48, 0.58) 0.33 (0.29, 0.37) 0.08 (0.06, 0.10) 0.06 (0.05, 0.08) 0.06 (0.04, 0.07) 
 Stage II 0.92 (0.85, 0.99) 0.56 (0.51, 0.62) 0.15 (0.12, 0.18) 0.09 (0.07, 0.11) 0.12 (0.10, 0.15) 
 Stage III 1.53 (1.38, 1.68) 1.01 (0.89, 1.14) 0.19 (0.14, 0.25) 0.11 (0.07, 0.15) 0.22 (0.17, 0.29) 
 Stage IV 4.79 (4.40, 5.20) 2.94 (2.64, 3.27) 0.94 (0.78, 1.14) 0.52 (0.40, 0.66) 0.39 (0.29, 0.52) 
Prostate  
 Overall 1.01 (0.97, 1.06) 0.55 (0.52, 0.58) 0.24 (0.22, 0.26) 0.13 (0.11, 0.15) 0.10 (0.08, 0.11) 
 Stage I 0.52 (0.43, 0.63) 0.25 (0.19, 0.33) 0.15 (0.10, 0.21) 0.07 (0.04, 0.12) 0.06 (0.03, 0.10) 
 Stage II 0.76 (0.71, 0.82) 0.45 (0.42, 0.49) 0.14 (0.12, 0.16) 0.10 (0.08, 0.12) 0.07 (0.05, 0.08) 
 Stage III 1.09 (0.94, 1.26) 0.67 (0.56, 0.80) 0.21 (0.15, 0.29) 0.10 (0.06, 0.16) 0.11 (0.07, 0.17) 
 Stage IV 3.31 (3.04, 3.60) 1.45 (1.28, 1.65) 1.09 (0.94, 1.26) 0.43 (0.34, 0.54) 0.34 (0.26, 0.44) 
Lung  
 Overall 6.75 (6.62, 6.89) 4.85 (4.74, 4.97) 0.91 (0.86, 0.96) 0.63 (0.59, 0.68) 0.37 (0.33, 0.40) 
 Stage I 2.51 (2.31, 2.72) 1.80 (1.64, 1.99) 0.29 (0.22, 0.36) 0.27 (0.21, 0.34) 0.15 (0.11, 0.21) 
 Stage II 4.09 (3.66, 4.56) 3.16 (2.78, 3.58) 0.51 (0.37, 0.70) 0.28 (0.18, 0.43) 0.13 (0.07, 0.24) 
 Stage III 6.67 (6.37, 6.98) 4.93 (4.67, 5.20) 0.79 (0.68, 0.90) 0.57 (0.48, 0.66) 0.39 (0.32, 0.47) 
 Stage IV 8.98 (8.77, 9.20) 6.39 (6.21, 6.58) 1.27 (1.18, 1.35) 0.86 (0.80, 0.94) 0.46 (0.41, 0.51) 
Colorectal  
 Overall 3.89 (3.79, 4.00) 2.28 (2.19, 2.36) 0.88 (0.83, 0.93) 0.43 (0.40, 0.47) 0.31 (0.28, 0.34) 
 Stage I 1.58 (1.43, 1.73) 0.91 (0.81, 1.03) 0.35 (0.29, 0.43) 0.18 (0.13, 0.24) 0.13 (0.09, 0.18) 
 Stage II 3.02 (2.83, 3.22) 1.71 (1.56, 1.86) 0.74 (0.65, 0.85) 0.37 (0.30, 0.44) 0.20 (0.16, 0.26) 
 Stage III 3.99 (3.78, 4.21) 2.37 (2.21, 2.54) 0.85 (0.75, 0.96) 0.44 (0.37, 0.51) 0.33 (0.28, 0.40) 
 Stage IV 7.55 (7.22, 7.88) 4.55 (4.30, 4.81) 1.64 (1.49, 1.80) 0.77 (0.67, 0.89) 0.59 (0.50, 0.69) 
NHL  
 Overall 4.34 (4.17, 4.51) 2.25 (2.13, 2.38) 1.14 (1.06, 1.23) 0.59 (0.53, 0.66) 0.35 (0.31, 0.41) 
 Stage I 3.21 (2.92, 3.51) 1.77 (1.57, 2.00) 0.67 (0.55, 0.82) 0.46 (0.36, 0.58) 0.30 (0.22, 0.40) 
 Stage II 4.17 (3.76, 4.61) 2.20 (1.90, 2.52) 1.02 (0.82, 1.25) 0.58 (0.44, 0.76) 0.37 (0.26, 0.52) 
 Stage III 4.72 (4.30, 5.17) 2.51 (2.21, 2.85) 1.26 (1.05, 1.50) 0.53 (0.40, 0.70) 0.41 (0.30, 0.56) 
 Stage IV 5.42 (5.11, 5.74) 2.70 (2.48, 2.93) 1.56 (1.39, 1.74) 0.76 (0.64, 0.88) 0.40 (0.32, 0.50) 
Uterine  
 Overall 3.73 (3.56, 3.90) 2.15 (2.02, 2.28) 0.94 (0.86, 1.03) 0.37 (0.32, 0.42) 0.27 (0.23, 0.33) 
 Stage I 1.47 (1.34, 1.61) 0.92 (0.82, 1.03) 0.31 (0.25, 0.38) 0.15 (0.11, 0.20) 0.09 (0.06, 0.13) 
 Stage II 3.80 (3.11, 4.57) 2.09 (1.59, 2.69) 0.95 (0.63, 1.38) 0.53 (0.31, 0.87) 0.23 (0.10, 0.48) 
 Stage III 6.61 (5.99, 7.26) 3.72 (3.26, 4.23) 1.90 (1.58, 2.28) 0.51 (0.36, 0.73) 0.47 (0.32, 0.67) 
 Stage IV 15.40 (14.3, 16.5) 8.61 (7.77, 9.52) 3.99 (3.41, 4.63) 1.67 (1.31, 2.11) 1.12 (0.83, 1.49) 
Bladder  
 Overall 5.10 (4.83, 5.37) 2.26 (2.08, 2.45) 1.82 (1.65, 1.99) 0.60 (0.51, 0.71) 0.42 (0.35, 0.51) 
 Stage I 1.70 (1.47, 1.96) 0.92 (0.75, 1.12) 0.52 (0.40, 0.67) 0.15 (0.09, 0.24) 0.11 (0.06, 0.19) 
 Stage II 5.69 (5.11, 6.31) 2.50 (2.12, 2.93) 2.07 (1.73, 2.47) 0.66 (0.48, 0.90) 0.45 (0.30, 0.66) 
 Stage III 8.16 (7.06, 9.35) 3.55 (2.84, 4.39) 3.06 (2.40, 3.84) 0.91 (0.58, 1.38) 0.64 (0.37, 1.05) 
 Stage IV 12.30 (11.3, 13.3) 5.16 (4.51, 5.87) 4.42 (3.82, 5.08) 1.62 (1.26, 2.04) 1.13 (0.84, 1.49) 
Stomach  
 Overall 6.68 (6.37, 7.00) 4.17 (3.93, 4.43) 1.31 (1.17, 1.46) 0.76 (0.65, 0.87) 0.45 (0.37, 0.54) 
 Stage I 3.36 (2.88, 3.90) 2.07 (1.69, 2.50) 0.69 (0.48, 0.96) 0.42 (0.26, 0.63) 0.19 (0.09, 0.35) 
 Stage II 5.23 (4.47, 6.08) 3.33 (2.72, 4.02) 1.02 (0.71, 1.44) 0.68 (0.43, 1.03) 0.20 (0.09, 0.43) 
 Stage III 6.65 (5.90, 7.46) 4.09 (3.50, 4.74) 1.33 (1.01, 1.73) 0.72 (0.49, 1.03) 0.51 (0.33, 0.78) 
 Stage IV 10.30 (9.64, 10.9) 6.51 (6.01, 7.04) 1.93 (1.66, 2.23) 1.09 (0.89, 1.33) 0.73 (0.57, 0.92) 
Pancreatic  
 Overall 10.70 (10.4, 11.1) 6.30 (6.05, 6.55) 2.41 (2.26, 2.57) 1.26 (1.15, 1.37) 0.79 (0.70, 0.88) 
 Stage I 5.28 (4.53, 6.11) 3.28 (2.69, 3.96) 0.99 (0.68, 1.39) 0.49 (0.29, 0.79) 0.52 (0.31, 0.83) 
 Stage II 7.68 (7.12, 8.26) 4.26 (3.84, 4.71) 1.71 (1.45, 2.01) 1.13 (0.92, 1.38) 0.58 (0.43, 0.76) 
 Stage III 7.81 (6.88, 8.83) 4.42 (3.72, 5.21) 2.02 (1.56, 2.58) 0.65 (0.41, 1.00) 0.72 (0.46, 1.08) 
 Stage IV 15.00 (14.5, 15.5) 8.95 (8.54, 9.38) 3.27 (3.01, 3.53) 1.74 (1.56, 1.94) 1.02 (0.88, 1.17) 
Ovarian  
 Overall 8.18 (7.83, 8.54) 5.17 (4.88, 5.46) 1.59 (1.43, 1.76) 0.83 (0.72, 0.96) 0.59 (0.50, 0.70) 
 Stage I 3.55 (3.06, 4.09) 2.12 (1.74, 2.55) 0.69 (0.48, 0.95) 0.38 (0.24, 0.59) 0.37 (0.23, 0.57) 
 Stage II 5.49 (4.49, 6.63) 3.37 (2.60, 4.30) 1.26 (0.81, 1.87) 0.34 (0.15, 0.73) 0.51 (0.26, 0.95) 
 Stage III 8.52 (7.91, 9.16) 5.50 (5.01, 6.03) 1.50 (1.25, 1.80) 1.03 (0.83, 1.28) 0.49 (0.35, 0.66) 
 Stage IV 12.50 (11.6, 13.3) 7.90 (7.25, 8.59) 2.43 (2.07, 2.83) 1.22 (0.97, 1.52) 0.90 (0.69, 1.16) 
Kidney  
 Overall 3.57 (3.40, 3.75) 1.99 (1.86, 2.12) 1.04 (0.95, 1.14) 0.35 (0.30, 0.41) 0.19 (0.15, 0.23) 
 Stage I 1.58 (1.42, 1.74) 1.05 (0.93, 1.19) 0.29 (0.22, 0.36) 0.18 (0.13, 0.24) 0.06 (0.04, 0.10) 
 Stage II 1.78 (1.40, 2.22) 0.84 (0.59, 1.15) 0.50 (0.31, 0.75) 0.32 (0.18, 0.54) 0.12 (0.05, 0.28) 
 Stage III 5.22 (4.69, 5.79) 2.44 (2.08, 2.85) 2.01 (1.68, 2.38) 0.41 (0.28, 0.60) 0.35 (0.23, 0.53) 
 Stage IV 9.02 (8.40, 9.66) 4.88 (4.42, 5.37) 2.82 (2.47, 3.20) 0.89 (0.70, 1.11) 0.43 (0.31, 0.60) 
Myeloma  
 Overall 5.34 (5.03, 5.67) 2.76 (2.53, 3.01) 1.32 (1.16, 1.49) 0.84 (0.72, 0.98) 0.42 (0.34, 0.52) 
Brain  
 Overall 9.70 (9.28, 10.1) 5.47 (5.15, 5.80) 2.20 (1.99, 2.41) 1.26 (1.11, 1.42) 0.78 (0.66, 0.91) 
Overall CATPE±DVTpDVTiDDVTLE-NOS, DVT
Cancer site% (95% CI)% (95% CI)% (95% CI)% (95% CI)% (95% CI)
Breast  
 Overall 1.04 (1.00, 1.09) 0.65 (0.62, 0.69) 0.17 (0.15, 0.19) 0.10 (0.09, 0.12) 0.12 (0.11, 0.14) 
 Stage I 0.53 (0.48, 0.58) 0.33 (0.29, 0.37) 0.08 (0.06, 0.10) 0.06 (0.05, 0.08) 0.06 (0.04, 0.07) 
 Stage II 0.92 (0.85, 0.99) 0.56 (0.51, 0.62) 0.15 (0.12, 0.18) 0.09 (0.07, 0.11) 0.12 (0.10, 0.15) 
 Stage III 1.53 (1.38, 1.68) 1.01 (0.89, 1.14) 0.19 (0.14, 0.25) 0.11 (0.07, 0.15) 0.22 (0.17, 0.29) 
 Stage IV 4.79 (4.40, 5.20) 2.94 (2.64, 3.27) 0.94 (0.78, 1.14) 0.52 (0.40, 0.66) 0.39 (0.29, 0.52) 
Prostate  
 Overall 1.01 (0.97, 1.06) 0.55 (0.52, 0.58) 0.24 (0.22, 0.26) 0.13 (0.11, 0.15) 0.10 (0.08, 0.11) 
 Stage I 0.52 (0.43, 0.63) 0.25 (0.19, 0.33) 0.15 (0.10, 0.21) 0.07 (0.04, 0.12) 0.06 (0.03, 0.10) 
 Stage II 0.76 (0.71, 0.82) 0.45 (0.42, 0.49) 0.14 (0.12, 0.16) 0.10 (0.08, 0.12) 0.07 (0.05, 0.08) 
 Stage III 1.09 (0.94, 1.26) 0.67 (0.56, 0.80) 0.21 (0.15, 0.29) 0.10 (0.06, 0.16) 0.11 (0.07, 0.17) 
 Stage IV 3.31 (3.04, 3.60) 1.45 (1.28, 1.65) 1.09 (0.94, 1.26) 0.43 (0.34, 0.54) 0.34 (0.26, 0.44) 
Lung  
 Overall 6.75 (6.62, 6.89) 4.85 (4.74, 4.97) 0.91 (0.86, 0.96) 0.63 (0.59, 0.68) 0.37 (0.33, 0.40) 
 Stage I 2.51 (2.31, 2.72) 1.80 (1.64, 1.99) 0.29 (0.22, 0.36) 0.27 (0.21, 0.34) 0.15 (0.11, 0.21) 
 Stage II 4.09 (3.66, 4.56) 3.16 (2.78, 3.58) 0.51 (0.37, 0.70) 0.28 (0.18, 0.43) 0.13 (0.07, 0.24) 
 Stage III 6.67 (6.37, 6.98) 4.93 (4.67, 5.20) 0.79 (0.68, 0.90) 0.57 (0.48, 0.66) 0.39 (0.32, 0.47) 
 Stage IV 8.98 (8.77, 9.20) 6.39 (6.21, 6.58) 1.27 (1.18, 1.35) 0.86 (0.80, 0.94) 0.46 (0.41, 0.51) 
Colorectal  
 Overall 3.89 (3.79, 4.00) 2.28 (2.19, 2.36) 0.88 (0.83, 0.93) 0.43 (0.40, 0.47) 0.31 (0.28, 0.34) 
 Stage I 1.58 (1.43, 1.73) 0.91 (0.81, 1.03) 0.35 (0.29, 0.43) 0.18 (0.13, 0.24) 0.13 (0.09, 0.18) 
 Stage II 3.02 (2.83, 3.22) 1.71 (1.56, 1.86) 0.74 (0.65, 0.85) 0.37 (0.30, 0.44) 0.20 (0.16, 0.26) 
 Stage III 3.99 (3.78, 4.21) 2.37 (2.21, 2.54) 0.85 (0.75, 0.96) 0.44 (0.37, 0.51) 0.33 (0.28, 0.40) 
 Stage IV 7.55 (7.22, 7.88) 4.55 (4.30, 4.81) 1.64 (1.49, 1.80) 0.77 (0.67, 0.89) 0.59 (0.50, 0.69) 
NHL  
 Overall 4.34 (4.17, 4.51) 2.25 (2.13, 2.38) 1.14 (1.06, 1.23) 0.59 (0.53, 0.66) 0.35 (0.31, 0.41) 
 Stage I 3.21 (2.92, 3.51) 1.77 (1.57, 2.00) 0.67 (0.55, 0.82) 0.46 (0.36, 0.58) 0.30 (0.22, 0.40) 
 Stage II 4.17 (3.76, 4.61) 2.20 (1.90, 2.52) 1.02 (0.82, 1.25) 0.58 (0.44, 0.76) 0.37 (0.26, 0.52) 
 Stage III 4.72 (4.30, 5.17) 2.51 (2.21, 2.85) 1.26 (1.05, 1.50) 0.53 (0.40, 0.70) 0.41 (0.30, 0.56) 
 Stage IV 5.42 (5.11, 5.74) 2.70 (2.48, 2.93) 1.56 (1.39, 1.74) 0.76 (0.64, 0.88) 0.40 (0.32, 0.50) 
Uterine  
 Overall 3.73 (3.56, 3.90) 2.15 (2.02, 2.28) 0.94 (0.86, 1.03) 0.37 (0.32, 0.42) 0.27 (0.23, 0.33) 
 Stage I 1.47 (1.34, 1.61) 0.92 (0.82, 1.03) 0.31 (0.25, 0.38) 0.15 (0.11, 0.20) 0.09 (0.06, 0.13) 
 Stage II 3.80 (3.11, 4.57) 2.09 (1.59, 2.69) 0.95 (0.63, 1.38) 0.53 (0.31, 0.87) 0.23 (0.10, 0.48) 
 Stage III 6.61 (5.99, 7.26) 3.72 (3.26, 4.23) 1.90 (1.58, 2.28) 0.51 (0.36, 0.73) 0.47 (0.32, 0.67) 
 Stage IV 15.40 (14.3, 16.5) 8.61 (7.77, 9.52) 3.99 (3.41, 4.63) 1.67 (1.31, 2.11) 1.12 (0.83, 1.49) 
Bladder  
 Overall 5.10 (4.83, 5.37) 2.26 (2.08, 2.45) 1.82 (1.65, 1.99) 0.60 (0.51, 0.71) 0.42 (0.35, 0.51) 
 Stage I 1.70 (1.47, 1.96) 0.92 (0.75, 1.12) 0.52 (0.40, 0.67) 0.15 (0.09, 0.24) 0.11 (0.06, 0.19) 
 Stage II 5.69 (5.11, 6.31) 2.50 (2.12, 2.93) 2.07 (1.73, 2.47) 0.66 (0.48, 0.90) 0.45 (0.30, 0.66) 
 Stage III 8.16 (7.06, 9.35) 3.55 (2.84, 4.39) 3.06 (2.40, 3.84) 0.91 (0.58, 1.38) 0.64 (0.37, 1.05) 
 Stage IV 12.30 (11.3, 13.3) 5.16 (4.51, 5.87) 4.42 (3.82, 5.08) 1.62 (1.26, 2.04) 1.13 (0.84, 1.49) 
Stomach  
 Overall 6.68 (6.37, 7.00) 4.17 (3.93, 4.43) 1.31 (1.17, 1.46) 0.76 (0.65, 0.87) 0.45 (0.37, 0.54) 
 Stage I 3.36 (2.88, 3.90) 2.07 (1.69, 2.50) 0.69 (0.48, 0.96) 0.42 (0.26, 0.63) 0.19 (0.09, 0.35) 
 Stage II 5.23 (4.47, 6.08) 3.33 (2.72, 4.02) 1.02 (0.71, 1.44) 0.68 (0.43, 1.03) 0.20 (0.09, 0.43) 
 Stage III 6.65 (5.90, 7.46) 4.09 (3.50, 4.74) 1.33 (1.01, 1.73) 0.72 (0.49, 1.03) 0.51 (0.33, 0.78) 
 Stage IV 10.30 (9.64, 10.9) 6.51 (6.01, 7.04) 1.93 (1.66, 2.23) 1.09 (0.89, 1.33) 0.73 (0.57, 0.92) 
Pancreatic  
 Overall 10.70 (10.4, 11.1) 6.30 (6.05, 6.55) 2.41 (2.26, 2.57) 1.26 (1.15, 1.37) 0.79 (0.70, 0.88) 
 Stage I 5.28 (4.53, 6.11) 3.28 (2.69, 3.96) 0.99 (0.68, 1.39) 0.49 (0.29, 0.79) 0.52 (0.31, 0.83) 
 Stage II 7.68 (7.12, 8.26) 4.26 (3.84, 4.71) 1.71 (1.45, 2.01) 1.13 (0.92, 1.38) 0.58 (0.43, 0.76) 
 Stage III 7.81 (6.88, 8.83) 4.42 (3.72, 5.21) 2.02 (1.56, 2.58) 0.65 (0.41, 1.00) 0.72 (0.46, 1.08) 
 Stage IV 15.00 (14.5, 15.5) 8.95 (8.54, 9.38) 3.27 (3.01, 3.53) 1.74 (1.56, 1.94) 1.02 (0.88, 1.17) 
Ovarian  
 Overall 8.18 (7.83, 8.54) 5.17 (4.88, 5.46) 1.59 (1.43, 1.76) 0.83 (0.72, 0.96) 0.59 (0.50, 0.70) 
 Stage I 3.55 (3.06, 4.09) 2.12 (1.74, 2.55) 0.69 (0.48, 0.95) 0.38 (0.24, 0.59) 0.37 (0.23, 0.57) 
 Stage II 5.49 (4.49, 6.63) 3.37 (2.60, 4.30) 1.26 (0.81, 1.87) 0.34 (0.15, 0.73) 0.51 (0.26, 0.95) 
 Stage III 8.52 (7.91, 9.16) 5.50 (5.01, 6.03) 1.50 (1.25, 1.80) 1.03 (0.83, 1.28) 0.49 (0.35, 0.66) 
 Stage IV 12.50 (11.6, 13.3) 7.90 (7.25, 8.59) 2.43 (2.07, 2.83) 1.22 (0.97, 1.52) 0.90 (0.69, 1.16) 
Kidney  
 Overall 3.57 (3.40, 3.75) 1.99 (1.86, 2.12) 1.04 (0.95, 1.14) 0.35 (0.30, 0.41) 0.19 (0.15, 0.23) 
 Stage I 1.58 (1.42, 1.74) 1.05 (0.93, 1.19) 0.29 (0.22, 0.36) 0.18 (0.13, 0.24) 0.06 (0.04, 0.10) 
 Stage II 1.78 (1.40, 2.22) 0.84 (0.59, 1.15) 0.50 (0.31, 0.75) 0.32 (0.18, 0.54) 0.12 (0.05, 0.28) 
 Stage III 5.22 (4.69, 5.79) 2.44 (2.08, 2.85) 2.01 (1.68, 2.38) 0.41 (0.28, 0.60) 0.35 (0.23, 0.53) 
 Stage IV 9.02 (8.40, 9.66) 4.88 (4.42, 5.37) 2.82 (2.47, 3.20) 0.89 (0.70, 1.11) 0.43 (0.31, 0.60) 
Myeloma  
 Overall 5.34 (5.03, 5.67) 2.76 (2.53, 3.01) 1.32 (1.16, 1.49) 0.84 (0.72, 0.98) 0.42 (0.34, 0.52) 
Brain  
 Overall 9.70 (9.28, 10.1) 5.47 (5.15, 5.80) 2.20 (1.99, 2.41) 1.26 (1.11, 1.42) 0.78 (0.66, 0.91) 

Models are stratified by cancer site and adjusted for the competing risk of death using Fine and Gray methodologies.

Models are additionally adjusted for age at cancer diagnosis, stage at cancer diagnosis, initial course of treatment (chemotherapy, radiation, and surgery), neighborhood socioeconomic status, and health insurance at diagnosis or initial treatment. Variables that violated proportional hazard assumption were included as a stratification variable.

All P values are significant <.01 by cancer site and stage at diagnosis and CAT location except: NHL (P value = .6025) and pancreas (P value = .0594).

LE-NOS DVT, lower extremity, not otherwise specified deep vein thrombosis.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal